Key Development
Vietnam’s most important pharmaceutical manufacturing gap is increasingly upstream. The country can manufacture finished medicines, but still produces only a small fraction of the ingredients inside them.
According to Ministry of Health data cited by Suc Khoe & Doi Song, Vietnam currently has only six registered pharmaceutical-ingredient manufacturing plants. Domestic production supplies roughly 5.2% of active pharmaceutical ingredient demand and 9.8% of excipient demand, even as domestic finished-drug manufacturing grows approximately 12–15% annually.
Decision 270/QD-TTg sets a 2030 target for domestic production to meet 20% of pharmaceutical raw-material demand and 50% of input demand for supplements and pharmaceutical cosmetics. This sits within a broader national strategy targeting domestically manufactured medicines to represent roughly 80% of consumption needs and 70% of market value by 2030.
Why It Matters
- Finished-dose capability does not equal supply security. A tablet may be manufactured domestically while its critical API and intermediates remain externally sourced.
- Moving from 5.2% toward 20% requires industrial scale. This is close to a fourfold increase in domestic share, not simply incremental laboratory capacity.
- Quality requirements are becoming more demanding. Vietnam Pharmacopoeia VI, effective July 1, 2026, contains 1,722 national standards, including 553 for chemical-pharmaceutical raw materials.
- API economics are structurally difficult. Commodity ingredients compete on scale, process yield, energy, environmental costs and procurement efficiency — areas where established Asian manufacturing hubs possess deep advantages.
Healthcare Insight Analysis
Healthcare Insight believes pharmaceutical self-reliance should not mean replacing every imported API with a Vietnamese equivalent regardless of cost.
That approach could create factories with high capital costs, low utilization and products that remain more expensive than imports.
A more credible model is selective pharmaceutical sovereignty.
The first priority should be critical APIs used in essential medicines where a supply interruption creates disproportionate public-health risk.
The second should be high-volume molecules where domestic demand can support commercially viable manufacturing scale.
The third should include high-value or technically differentiated ingredients, where Vietnam can compete through chemistry, manufacturing quality or intellectual property rather than unit cost alone.
The fourth is natural pharmaceutical ingredients, an area where Vietnam possesses potentially differentiated biological resources. Decision 270 targets export growth above 10% annually for selected natural pharmaceutical products, while domestic programs are developing standardized medicinal-plant supply chains and compounds derived from resources such as Ngoc Linh ginseng.
The industrial challenge, however, extends far beyond building reactors.
Commercial API manufacturing requires process chemistry, impurity characterization, analytical methods, environmental controls, industrial scale-up and regulatory documentation reliable enough for pharmaceutical customers to incorporate the ingredient into registered medicines.
This is the difficult transition from:
“we can synthesize it”
to
“we can repeatedly manufacture it at commercial scale, regulatory quality and competitive cost.”
That distinction should also change how policy success is measured.
Counting new factories is insufficient.
A stronger KPI is how many locally produced APIs achieve sustained commercial adoption by pharmaceutical manufacturers.
Vietnam’s 20% target therefore should not be interpreted as an autarky target. The more strategic objective is to reduce concentration risk while moving upstream into portions of the pharmaceutical value chain where domestic capability can become economically sustainable.
Market Implications
Pharmaceutical manufacturers: vertical integration can improve resilience, but investment should concentrate on molecules with sufficient volume or strategic importance.
Chemical companies: the opportunity extends beyond finished APIs into intermediates, fine chemicals, solvents and specialty chemistry.
Investors: capacity utilization, process yield, wastewater-treatment economics and committed offtake will matter more than announced plant capacity.
Universities and research institutes: value creation increasingly depends on technology transfer and industrial scale-up rather than laboratory results alone.
ANALYTICAL MATRIX
| Dimension | Current Position | Opportunity / Target | Key Risk |
| APIs | ~5.2% of demand domestically supplied | 20% raw-material target by 2030 | Scale and cost competitiveness |
| Infrastructure | Six registered ingredient plants | Build industrial capabilities | Low utilization |
| Quality | Rising pharmacopoeial standards | Enter higher-value supply chains | Compliance cost |
| Natural products | Local biological resources | Differentiated high-value ingredients | Standardization and traceability |
| Strategy | High external dependence | Selective localization | Over-expansion into commodity APIs |
The two metrics worth watching through 2030 are not merely the percentage of raw materials produced domestically, but also API-plant utilization and the share of locally manufactured ingredients actually incorporated into commercial medicines.
Building factories creates capacity. Building the right molecules, technology and customer base creates something much harder — a pharmaceutical-chemicals industry.